AstraZeneca To Present Overall Survival Data From Four Pivotal Phase III Trials Featuring Sone-Ve, IMFINZI, TAGRISSO And Savolitinib

AstraZeneca will present data from four Phase III trials at ESMO 2026, featuring Sone-Ve, IMFINZI, TAGRISSO, and savolitinib. Key trials include CLARITY-Gastric01 for Sone-Ve in gastric cancer, SAFFRON for TAGRISSO plus savolitinib in lung cancer, and VOLGA and DeLLphi-305 for IMFINZI combinations in bladder and lung cancers. The company aims to showcase the potential of these treatments to set new standards of care.

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

AstraZeneca will present over 100 study abstracts at the 2026 ESMO Congress, including five Phase III trials. Key trials involve Sonesitatug vedotin for gastric cancer, Tagrisso and Orpathys for lung cancer, and Imfinzi combinations for bladder and lung cancers. Additional data will cover early-stage trials in lung, ovarian, and liver cancers.

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

AstraZeneca will present overall survival data from four pivotal Phase III trials at ESMO 2026, featuring Sone-Ve, Imfinzi, Tagrisso, and Orpathys. The trials focus on bladder, lung, and gastric cancers, showcasing innovative combinations and precision medicine. Key data includes CLARITY-Gastric01 for Sone-Ve, SAFFRON for Tagrisso plus Orpathys, and VOLGA and DeLLphi-305 for Imfinzi combinations. AstraZeneca aims to redefine cancer treatment standards with these findings.

AstraZeneca (AZN) reported that efzimfotase alfa improved 6MWT by 61.9m in HICKORY extension. CHMP recommended expanding AZN's H5N1 vaccine use. Jefferies sees upside if AZN confirms guidance and improves ops. AZN signed MoU with University of Liverpool for industry ties and internships.